References
- Lum BL, Torn FM. Adjuvant intravesicular pharma-cotherapy for superficial bladder cancer. J Natl Cancer Inst 1991; 83: 682–94.
- Ikeda N, Shimada Y, Ohtsu A, Boku N, Tsuji Y, Saito H, et al. A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410). Jpn J Clin Oncol 2002; 32: 90–4.
- Bajetta E, Colleoni M, Rosso R, Sobrero A, Amadori D, Comella G, et al. Prospective randomized trial compar-ing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 1993; 29: 1658–63.
- Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, et al. Randomized controlled trial com-paring oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. J Clin Oncol 2003; 21: 991–8.
- Matsushima H, Kawabe K, Fujime M, Kitamura T, Homma Y, Kishi H, et al. Treatment of patients with superficial bladder cancer by intravesical instillation of anticancer drugs plus oral chemotherapy following TUR-Bt: a randomized controlled trial. Oncol Rep 2002; 9: 283–8.
- O'Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endo-thelial cell growth factor in primary bladder cancers. Cancer Res 1996; 56: 4799–804.
- Sawase K, Nomata K, Kanetake H, Saito Y. The expression of platelet-derived endothelial cell growth factor in human bladder cancer. Cancer Lett 1998; 130: 35–41.
- Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemo-sensitivity to fluorouracil-related drugs. Anticancer Res 2000; 20: 4315–8.
- Arima J, Imazono Y, Takebayashi Y, Nishiyama K, Shirahama T, Akiba S, et al. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000; 88: 1131–8.
- Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by trans-urethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999; 86: 1818–26.
- Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mito-mycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161: 1120–3.
- Richter R, Jiang F, Gorog J-P, Sartorius G, Egenter C, Gasser T, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997; 57: 2860–4.
- Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 2002; 38: 2375–81.